{"id":802039,"date":"2025-01-17T08:05:58","date_gmt":"2025-01-17T13:05:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-realigns-pipeline-strategy-empowering-drug-discovery-with-ai-and-first-principles-innovation\/"},"modified":"2025-01-17T08:05:58","modified_gmt":"2025-01-17T13:05:58","slug":"immunoprecise-antibodies-realigns-pipeline-strategy-empowering-drug-discovery-with-ai-and-first-principles-innovation","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-realigns-pipeline-strategy-empowering-drug-discovery-with-ai-and-first-principles-innovation\/","title":{"rendered":"ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation"},"content":{"rendered":"

<\/p>\n

ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation<\/b><\/p>\n

AUSTIN, Texas–(BUSINESS WIRE<\/a>)–
\nImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) today announced the launch of its AI-powered pipeline<\/a> of both optimized and new therapeutics, a system set to transform therapeutic development. By combining advanced artificial intelligence with first-principles thinking, the BioStrand pipeline reimagines drug discovery, offering unmatched speed, precision, and transparency.<\/p>\n

\nTraditional drug discovery often builds on outdated frameworks, layering new tools onto existing systems and perpetuating inefficiencies. IPA\u2019s first-principles approach breaks from this mold by deconstructing challenges to their fundamentals and rebuilding processes from the ground up. This mindset led to the creation of LENSai<\/sup>, IPA\u2019s proprietary AI platform, which organizes vast biological datasets into a unified framework, eliminating silos and accelerating discoveries.<\/p>\n

\nThe IPA pipeline introduces a new era of AI-enhanced therapies designed to meet modern medical demands while addressing critical unmet needs. By pairing cutting-edge computational insights with rigorous lab validation, IPA ensures the delivery of treatments that are not only groundbreaking but also highly effective and reliable.<\/p>\n

\nPowered by LENSai<\/sup>‘s in silico <\/i>workflows, the pipeline integrates data with precision at every stage of development, enabling therapies that are faster, more targeted, and impactful for the future of medicine.<\/p>\n

\n“Our AI-powered pipeline<\/a> represents a major leap forward for IPA,” said Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies. “By harnessing AI and rethinking drug discovery from the ground up, we are not just improving the process\u2014we are fundamentally changing what\u2019s possible. This pipeline lays the foundation for groundbreaking advancements in therapeutic development, embodying our vision of innovation driven by clarity, precision, and purpose.”<\/p>\n

\nThis launch marks a pivotal moment for IPA as it continues to set new standards in biotherapeutics. By tackling complex therapeutic challenges and addressing some of the world\u2019s most pressing medical needs, IPA is poised to lead the next wave of AI-powered drug discovery.<\/p>\n

About ImmunoPrecise Antibodies Ltd.<\/b><\/p>\n

\nImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the \u201cIPA Family\u201d).<\/p>\n

Forward-Looking Statements<\/i><\/b><\/p>\n

\nThis press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements often include words such as \u201cexpects,\u201d \u201cintends,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d or variations thereof, or state that certain actions, events, or results \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d or \u201cmight\u201d occur. These statements relate to, among other things, the anticipated benefits and impact of the AI-driven pipeline, the potential for AI-enhanced therapeutic assets to accelerate drug discovery, and the Company\u2019s ability to develop and commercialize new therapeutic candidates.<\/p>\n

\nAlthough the Company believes it has a reasonable basis for these forward-looking statements, they are based on current expectations, assumptions, and projections about future events that involve risks and uncertainties. Actual results may differ materially from those expressed or implied due to factors largely beyond the Company\u2019s control, including risks related to scientific and technological developments, regulatory approvals, industry competition, and broader market conditions.<\/p>\n

\nForward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information on risks and uncertainties can be found in the Company\u2019s Annual Report on Form 20-F, as amended, for the year ended April 30, 2024 (available on the Company\u2019s SEDAR+ profile at www.sedarplus.ca<\/a> and EDGAR profile at www.sec.gov\/edgar<\/a>). Should any of these risks materialize, actual results could vary significantly.<\/p>\n

\nReaders are cautioned not to place undue reliance on forward-looking statements, which reflect the Company\u2019s expectations only as of the date of this release. The Company assumes no obligation to update or revise these statements, except as required by law.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250117288652\/en\/<\/a><\/span><\/p>\n

Investor Relations Contact
\n<\/b>
investors@ipatherapeutics.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America Texas<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Technology Other Health Health Other Science Other Technology Research Infectious Diseases Software Artificial Intelligence Science<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation AUSTIN, Texas–(BUSINESS WIRE)– ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) today announced the launch of its AI-powered pipeline of both optimized and new therapeutics, a system set to transform therapeutic development. By combining advanced artificial intelligence with first-principles thinking, the BioStrand pipeline reimagines drug discovery, offering unmatched speed, precision, and transparency. Traditional drug discovery often builds on outdated frameworks, layering new tools onto existing systems and perpetuating inefficiencies. IPA\u2019s first-principles approach breaks from this mold by deconstructing challenges to their fundamentals and rebuilding processes from the ground up. This mindset led to the creation of LENSai, IPA\u2019s proprietary AI platform, which organizes vast biological datasets into a unified framework, … <\/p>\n

Continue reading “ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-802039","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-realigns-pipeline-strategy-empowering-drug-discovery-with-ai-and-first-principles-innovation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation AUSTIN, Texas–(BUSINESS WIRE)– ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) today announced the launch of its AI-powered pipeline of both optimized and new therapeutics, a system set to transform therapeutic development. By combining advanced artificial intelligence with first-principles thinking, the BioStrand pipeline reimagines drug discovery, offering unmatched speed, precision, and transparency. Traditional drug discovery often builds on outdated frameworks, layering new tools onto existing systems and perpetuating inefficiencies. IPA\u2019s first-principles approach breaks from this mold by deconstructing challenges to their fundamentals and rebuilding processes from the ground up. This mindset led to the creation of LENSai, IPA\u2019s proprietary AI platform, which organizes vast biological datasets into a unified framework, … Continue reading "ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-realigns-pipeline-strategy-empowering-drug-discovery-with-ai-and-first-principles-innovation\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-17T13:05:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250117288652r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-antibodies-realigns-pipeline-strategy-empowering-drug-discovery-with-ai-and-first-principles-innovation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-antibodies-realigns-pipeline-strategy-empowering-drug-discovery-with-ai-and-first-principles-innovation\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation\",\"datePublished\":\"2025-01-17T13:05:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-antibodies-realigns-pipeline-strategy-empowering-drug-discovery-with-ai-and-first-principles-innovation\\\/\"},\"wordCount\":734,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-antibodies-realigns-pipeline-strategy-empowering-drug-discovery-with-ai-and-first-principles-innovation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250117288652r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-antibodies-realigns-pipeline-strategy-empowering-drug-discovery-with-ai-and-first-principles-innovation\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-antibodies-realigns-pipeline-strategy-empowering-drug-discovery-with-ai-and-first-principles-innovation\\\/\",\"name\":\"ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-antibodies-realigns-pipeline-strategy-empowering-drug-discovery-with-ai-and-first-principles-innovation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-antibodies-realigns-pipeline-strategy-empowering-drug-discovery-with-ai-and-first-principles-innovation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250117288652r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-01-17T13:05:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-antibodies-realigns-pipeline-strategy-empowering-drug-discovery-with-ai-and-first-principles-innovation\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-antibodies-realigns-pipeline-strategy-empowering-drug-discovery-with-ai-and-first-principles-innovation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-antibodies-realigns-pipeline-strategy-empowering-drug-discovery-with-ai-and-first-principles-innovation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250117288652r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250117288652r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-antibodies-realigns-pipeline-strategy-empowering-drug-discovery-with-ai-and-first-principles-innovation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-realigns-pipeline-strategy-empowering-drug-discovery-with-ai-and-first-principles-innovation\/","og_locale":"en_US","og_type":"article","og_title":"ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation - Market Newsdesk","og_description":"ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation AUSTIN, Texas–(BUSINESS WIRE)– ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) today announced the launch of its AI-powered pipeline of both optimized and new therapeutics, a system set to transform therapeutic development. By combining advanced artificial intelligence with first-principles thinking, the BioStrand pipeline reimagines drug discovery, offering unmatched speed, precision, and transparency. Traditional drug discovery often builds on outdated frameworks, layering new tools onto existing systems and perpetuating inefficiencies. IPA\u2019s first-principles approach breaks from this mold by deconstructing challenges to their fundamentals and rebuilding processes from the ground up. This mindset led to the creation of LENSai, IPA\u2019s proprietary AI platform, which organizes vast biological datasets into a unified framework, … Continue reading \"ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-realigns-pipeline-strategy-empowering-drug-discovery-with-ai-and-first-principles-innovation\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-17T13:05:58+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250117288652r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-realigns-pipeline-strategy-empowering-drug-discovery-with-ai-and-first-principles-innovation\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-realigns-pipeline-strategy-empowering-drug-discovery-with-ai-and-first-principles-innovation\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation","datePublished":"2025-01-17T13:05:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-realigns-pipeline-strategy-empowering-drug-discovery-with-ai-and-first-principles-innovation\/"},"wordCount":734,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-realigns-pipeline-strategy-empowering-drug-discovery-with-ai-and-first-principles-innovation\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250117288652r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-realigns-pipeline-strategy-empowering-drug-discovery-with-ai-and-first-principles-innovation\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-realigns-pipeline-strategy-empowering-drug-discovery-with-ai-and-first-principles-innovation\/","name":"ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-realigns-pipeline-strategy-empowering-drug-discovery-with-ai-and-first-principles-innovation\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-realigns-pipeline-strategy-empowering-drug-discovery-with-ai-and-first-principles-innovation\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250117288652r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-01-17T13:05:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-realigns-pipeline-strategy-empowering-drug-discovery-with-ai-and-first-principles-innovation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-realigns-pipeline-strategy-empowering-drug-discovery-with-ai-and-first-principles-innovation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-realigns-pipeline-strategy-empowering-drug-discovery-with-ai-and-first-principles-innovation\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250117288652r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250117288652r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-realigns-pipeline-strategy-empowering-drug-discovery-with-ai-and-first-principles-innovation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/802039","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=802039"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/802039\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=802039"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=802039"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=802039"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}